Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Advisors Asset Management Inc.

Advisors Asset Management Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO) by 33.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,100 shares of the company’s stock after buying an additional 17,035 shares during the quarter. Advisors Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $8,744,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. EP Wealth Advisors LLC lifted its holdings in Novo Nordisk A/S by 4.2% in the 1st quarter. EP Wealth Advisors LLC now owns 47,862 shares of the company’s stock worth $6,146,000 after buying an additional 1,935 shares in the last quarter. OLD Mission Capital LLC acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $5,291,000. Wellington Wealth Strategies LLC. acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $2,294,000. CreativeOne Wealth LLC raised its stake in shares of Novo Nordisk A/S by 223.6% in the 1st quarter. CreativeOne Wealth LLC now owns 17,558 shares of the company’s stock valued at $2,254,000 after purchasing an additional 12,132 shares in the last quarter. Finally, Vident Advisory LLC raised its stake in shares of Novo Nordisk A/S by 4.2% in the 1st quarter. Vident Advisory LLC now owns 31,522 shares of the company’s stock valued at $4,048,000 after purchasing an additional 1,258 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $1.14 during mid-day trading on Friday, reaching $126.72. 3,178,103 shares of the company traded hands, compared to its average volume of 4,424,668. Novo Nordisk A/S has a fifty-two week low of $77.96 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The firm has a market cap of $568.66 billion, a PE ratio of 43.70, a price-to-earnings-growth ratio of 1.32 and a beta of 0.41. The stock has a fifty day simple moving average of $138.79 and a 200-day simple moving average of $128.11.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The business had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday, July 1st. BMO Capital Markets restated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Finally, Argus boosted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.